Skip to main content
Research and Innovation

New Ultrasound ‘Drill’ Targets Deep Vein Blood Clots

Researchers have developed the first ultrasound “drill” that can be aimed straight ahead, allowing doctors to better target clots. The tool also incorporates an injection tube that allows users to inject microbubbles at the site of the clot, making the ultrasound waves more effective.

For Immediate Release

Researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a new surgical tool that uses low-frequency intravascular ultrasound to break down blood clots that cause deep vein thrombosis. The tool is the first ultrasound “drill” that can be aimed straight ahead, allowing doctors to better target clots – which holds promise for significantly reducing treatment time. To date, the technology has been tested only in synthetic blood vessels.

Existing intravascular ultrasound tools for clearing clots emit ultrasound waves laterally. This makes it harder to target clots exclusively, meaning that the ultrasound can also damage surrounding blood vessels. However, ultrasound breaks the clots into very small pieces, so doctors don’t need to use large doses of blood thinner to dissolve the clot remnants.

Another technique uses a diamond-tipped drill to effectively chew through clots. This is more targeted, posing less risk to blood vessels. However, this technique breaks the clot into relatively large pieces, requiring higher doses of blood-thinning drugs – which can pose risks of their own.

“Our new ultrasound tool is forward-facing, like a drill, but still breaks down clots into very fine particles,” says Xiaoning Jiang, a professor of mechanical and aerospace engineering at NC State and corresponding author of a paper describing the work. “Our approach improves accuracy without relying on high doses of blood thinners, which we hope will reduce risks across the board.”

The tool also incorporates an injection tube that allows users to inject microbubbles at the site of the clot, making the ultrasound waves more effective at breaking down the clot.

The researchers tested a prototype of the device in a synthetic blood vessel using cow’s blood.

“We found that we could dissolve 90 percent of a clot in 3.5 to 4 hours without using any blood thinners at all,” says Jinwook Kim, lead author of the paper and a Ph.D. student in Jiang’s lab. “That’s compared to 10 hours for the combination of conventional ultrasound tools and blood thinners.”

“This is a successful proof of concept, and we’re now in the process of securing funding to move forward with trials in an animal model,” Jiang says.

The researchers have filed a patent on the technology and are interested in working with industry partners to help develop the device.

The paper, “Intravascular forward-looking ultrasound transducers for microbubble-mediated sonothrombolysis,” is published in the Nature Publishing Group journal Scientific Reports. Paper co-authors include Wei-Yi Chang of NC State; Brooks Lindsey and Paul Dayton of the Joint Department of Biomedical Engineering at NC State and UNC; and Xuming Dai and Joseph Stavas of UNC. The work is funded, in part, by the National Institutes of Health under grant R01EB015508.


Note to Editors: The study abstract follows.

“Intravascular forward-looking ultrasound transducers for microbubble-mediated sonothrombolysis”

Authors: Jinwook Kim, Wei-Yi Chang and Xiaoning Jiang, North Carolina State University; Brooks D. Lindsey and Paul A. Dayton, North Carolina State University and the University of North Carolina at Chapel Hill; Xuming Dai and Joseph M. Stavas, the University of North Carolina at Chapel Hill.

Published: June 14, Scientific Reports

DOI: 10.1038/s41598-017-03492-4

Abstract: Effective removal or dissolution of large blood clots remains a challenge in clinical treatment of acute thrombo-occlusive diseases. Here we report the development of an intravascular microbubble-mediated sonothrombolysis device for improving thrombolytic rate and thus minimizing the required dose of thrombolytic drugs. We hypothesize that a sub-megahertz, forward-looking ultrasound transducer with an integrated microbubble injection tube is more advantageous for efficient thrombolysis by enhancing cavitation-induced microstreaming than the conventional high-frequency, side-looking, catheter-mounted transducers. We developed custom miniaturized transducers and demonstrated that these transducers are able to generate sufficient pressure to induce cavitation of lipid-shelled microbubble contrast agents. Our technology demonstrates a lytic rate of 0.7±0.15 percent mass loss/min in vitro without any use of thrombolytic drugs.

Leave a Reply to Dina Kim Cancel reply

Your email address will not be published. All fields are required.

  1. Dear colleagues !

    My name is Vera Luttseva, and I am a Business Development Manager at AmeRuss Clinical Trials. The theme of intravascular ultrasound tools and surgical devices is close to us, and we are actively looking for partners for conducting comprehensive clinical trials of such products in Russia and other countries of our operational region.

    AmeRuss is a modern CRO with clinical operations in the markets of Russia, the former USSR countries and the neighbors. We are a full-fledged CRO, well-known for carrying out clinical studies in extensive surgical and therapeutic fields. Our company has long-term partnerships with the largest scientific research institutions, laboratories and we are able to maintain high patient enrollment rates and ensure high profitability of our solutions.

    The company is also authorized to conduct high-quality clinical trials in four strategic regions of the CIS: Georgia, Armenia, Belarus and Kazakhstan, which demonstrate a very high potential for large-scale clinical trials and ensure high quality data.

    We support all stages of clinical development, including clinical studies “First-in-Man”, Phase II-III and post-marketing (observation / registries).

    I will be glad to discuss in more detail whether our offer is interesting for you, and how we can provide clinical trials of your products in our regions.
    Please let me know if you are interested in calling me or receiving more information about AmeRuss.